Intended Audience
Internet-based program
Method of Physician Participation Utilized in Learning Process
There are no fees for participating and receiving CME credit for this activity. During the period January 4, 2011 through January 4, 2013 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) register and complete the evaluation form; and 4) print out CME certificate.
Estimated Time to Complete Educational Activity
4.0 hours
Course Overview
In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in thrombosis prevention in the setting of cancer.
Release Date
January 4, 2011
Expiration Date
January 4 2013
Registration
Enrollment for this iQ&A interactive Medical Intelligence Zone is complimentary, and clinicians are invited to participate in this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
Grantor Support
Supported by independent educational grants from sanofi-aventis and Eisai, Inc.
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Massachusetts Medical School designates this enduring activity for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Policy on Faculty & Provider Disclosure
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Program Faculty and Disclosure
Charles W. Francis, MD
Professor of Medicine and Pathology and Laboratory Medicine
Department of Medicine
University of Rochester
School of Medicine and Dentistry
Rochester, NY
Consultant: Boehringer-Ingelheim
Grant/Research Support: Eisai
Samuel Z. Goldhaber, MD
Professor of Medicine
Harvard Medical School
Director, VTE Research Group
Cardiovascular Division
Brigham and Women's Hospital
President, North American Thrombosis Forum (NATF)
Boston, Massachusetts
Advisor or consultant: Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Eisai, and sanofi-aventis.
Research support: Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eisai, Johnson & Johnson Pharmaceutical Research & Development and sanofi-aventis.
Ajay Kakkar, MBBS, PhD, FRCS
Head of the Centre for Surgical Sciences
Barts and the London
Queen Mary's School of Medicine and Dentistry
Thrombosis Research Institute
London, UK
Consultant: Pfizer, Bristol-Myers, Squibb, sanofi0aventis, Boehringer-Ingelnheim, Bayer, GlaxoSmithKline, Eisai, Aryx
Grant/Research Support: Pfizer, Bristol-Myers, Squibb, sanofi0aventis, Boehringer-Ingelnheim, Bayer, GlaxoSmithKline, Eisai, Aryx
Craig Kessler, MD
Professor of Medicine
Department of Hematology
Anticoagulation Services
Georgetown University Medical Center
Washington, DC
Consultant: sanofi-aventis, Eisai
Speaker's Bureau: sanofi-aventis, Eisai
Alok A. Khorana, MD, FACP
Vice-Chief, Division of Hematology/Oncology
Associate Professor of Medicine and Oncology, James P. Wilmot Cancer Center
University of Rochester
Rochester, NY
Consultant: Sanofi-Aventis, Eisai, Leo Pharma
Speaker's Bureau: Sanofi-Aventis, Leo Pharma
Grant/Research Support: sanofi-aventis
Frederick R. Rickles, MD
Clinical Professor of Medicine, Pediatrics, Pharmacology and Physiology
Division of Hematology-Oncology
Department of Medicine
The George Washington University School of Medicine and Health Sciences
Washington, DC
Consultant: Genmab, Bayer/Ortho-McNeil/J & J, Pharmacyclics, Leo
Speaker's Bureau: Eisai
Educational Objectives
Participants in this CME-certified iQandA will learn:
Disclaimer
Copyright © 2011 by Pharmatecture, LLC and CMEducation Resources, LLC All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.
Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.
- Oncology specialists
- Surgical oncology specialists
- VTE and thrombosis specialists
- Hematology/oncology specialists
- Hospital pharmacists
- Anticoagulation specialists
- Hospitalists
- Oncology nurses and NPs
Internet-based program
Method of Physician Participation Utilized in Learning Process
There are no fees for participating and receiving CME credit for this activity. During the period January 4, 2011 through January 4, 2013 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) register and complete the evaluation form; and 4) print out CME certificate.
Estimated Time to Complete Educational Activity
4.0 hours
Course Overview
In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in thrombosis prevention in the setting of cancer.
Release Date
January 4, 2011
Expiration Date
January 4 2013
Registration
Enrollment for this iQ&A interactive Medical Intelligence Zone is complimentary, and clinicians are invited to participate in this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
Grantor Support
Supported by independent educational grants from sanofi-aventis and Eisai, Inc.
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Massachusetts Medical School designates this enduring activity for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Policy on Faculty & Provider Disclosure
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Program Faculty and Disclosure
Charles W. Francis, MD
Professor of Medicine and Pathology and Laboratory Medicine
Department of Medicine
University of Rochester
School of Medicine and Dentistry
Rochester, NY
Consultant: Boehringer-Ingelheim
Grant/Research Support: Eisai
Samuel Z. Goldhaber, MD
Professor of Medicine
Harvard Medical School
Director, VTE Research Group
Cardiovascular Division
Brigham and Women's Hospital
President, North American Thrombosis Forum (NATF)
Boston, Massachusetts
Advisor or consultant: Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Eisai, and sanofi-aventis.
Research support: Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eisai, Johnson & Johnson Pharmaceutical Research & Development and sanofi-aventis.
Ajay Kakkar, MBBS, PhD, FRCS
Head of the Centre for Surgical Sciences
Barts and the London
Queen Mary's School of Medicine and Dentistry
Thrombosis Research Institute
London, UK
Consultant: Pfizer, Bristol-Myers, Squibb, sanofi0aventis, Boehringer-Ingelnheim, Bayer, GlaxoSmithKline, Eisai, Aryx
Grant/Research Support: Pfizer, Bristol-Myers, Squibb, sanofi0aventis, Boehringer-Ingelnheim, Bayer, GlaxoSmithKline, Eisai, Aryx
Craig Kessler, MD
Professor of Medicine
Department of Hematology
Anticoagulation Services
Georgetown University Medical Center
Washington, DC
Consultant: sanofi-aventis, Eisai
Speaker's Bureau: sanofi-aventis, Eisai
Alok A. Khorana, MD, FACP
Vice-Chief, Division of Hematology/Oncology
Associate Professor of Medicine and Oncology, James P. Wilmot Cancer Center
University of Rochester
Rochester, NY
Consultant: Sanofi-Aventis, Eisai, Leo Pharma
Speaker's Bureau: Sanofi-Aventis, Leo Pharma
Grant/Research Support: sanofi-aventis
Frederick R. Rickles, MD
Clinical Professor of Medicine, Pediatrics, Pharmacology and Physiology
Division of Hematology-Oncology
Department of Medicine
The George Washington University School of Medicine and Health Sciences
Washington, DC
Consultant: Genmab, Bayer/Ortho-McNeil/J & J, Pharmacyclics, Leo
Speaker's Bureau: Eisai
Educational Objectives
Participants in this CME-certified iQandA will learn:
- Apply NCCN, ASCO, and ACCP guidelines aimed at preventing primary and recurrent VTE in patients with cancer.
- Assess patients with cancer, both in the inpatient and outpatient setting, and their likelihood for sustaining an initial or recurrent VTE; and, what the implications of their risk score is for prophylaxis management.
- Compare the safety, efficacy, costs of monitoring, and long-term outcomes of vitamin K antagonists versus LMWHs when managing cancer patients who require secondary prevention of VTE.
- Apply the results of landmark clinical trials in cancer and thrombosis to the front lines of oncology and surgical oncology care.
- Explain the mechanisms of thrombosis formation in cancer and the effects of LWMHs on inhibition of the coagulation cascade and on angiogenesis.
Disclaimer
Copyright © 2011 by Pharmatecture, LLC and CMEducation Resources, LLC All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.
Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.
Copyright © CMEducation Resources, LLC and Pharmatecture, LLC
Click here to indicate that you have read this CME information statement and wish to participate in this CME activity.
